Intra-Cellular Therapies Announces Multiple Presentations on ITI-007 at the 4th Biennial Schizophrenia International Research Society (SIRS) Conference
GlobeNewswire - Mon Apr 07, 7:00AM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders has presented several posters and a talk at the 4th Biennial Schizophrenia International Research Society (SIRS) conference being held in Florence, Italy.
Intra-Cellular Therapies Announces Upcoming Presentations at the 4th Biennial Schizophrenia International Research Society Conference
GlobeNewswire - Wed Apr 02, 10:20AM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that one oral presentation and four posters on ITI-007, the Company's lead drug candidate for the treatment of schizophrenia, behavioral disturbances in dementia, bipolar disorder and other neuropsychiatric and neurological disorders, will be featured at the 4 Biennial Schizophrenia International Research Society (SIRS) Conference. The meeting will be held April 5-9, 2014, in Florence, Italy. The presentation and posters will feature data from ITI-007-005, the Company's recently completed Phase 2 clinical trial in patients with an acutely exacerbated episode of schizophrenia, as well as data on the metabolism, unique target profile, and mechanism of action of ITI-007.
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2013 Financial Results
GlobeNewswire - Tue Mar 25, 3:01PM CDT
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and year ended December 31, 2013, and provided an update on corporate developments and upcoming events.
Intra-Cellular Therapies to Announce 2013 Fourth Quarter And Full Year Financial Results and to Host Conference Call on Tuesday, March 25, at 4:30 pm Eastern Time
PR Newswire - Tue Mar 18, 3:00PM CDT
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and a live Internet webcast at 4:30 p.m. Eastern Time on Tuesday March 25, 2014 to discuss the financial results for the fourth quarter and year ended December 31, 2013.
Intra-Cellular Therapies hires Dr Juan Sanchez as VP of Corporate Communications and Investor Relations
M2 - Tue Mar 11, 5:59AM CDT
Biopharmaceutical company Intra-Cellular Therapies (NasdaqGS :ITCI) revealed on Monday the election of Juan Sanchez MD, as vice president of its Corporate Communications and Investor Relations.
Intra-Cellular Therapies Announces the Appointment of Juan Sanchez, M.D., as Vice President of Corporate Communications and Investor Relations
PR Newswire - Mon Mar 10, 6:30AM CDT
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the appointment of Juan Sanchez, M.D., as Vice President of Corporate Communications and Investor Relations. Dr. Sanchez will report to Sharon Mates, Ph.D., CEO and Chairman of Intra-Cellular Therapies.
Intra-Cellular Therapies Announces Initiation of Phase I/II Clinical Trial for ITI-007 in Healthy Geriatric Subjects and Patients with Dementia, Including Alzheimer's Disease
PR Newswire - Mon Mar 03, 6:00AM CST
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the initiation of ITI-007-200, a Phase I/II clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of low doses of its lead drug candidate, ITI-007, in healthy geriatric subjects and in patients with dementia, including Alzheimer's disease. The commencement of this study marks an important milestone in our strategy to develop low doses of ITI-007 for the treatment of behavioral disturbances associated with dementia and related disorders.
Intra-Cellular Therapies to Present at the Cowen and Company 34th Annual Healthcare Conference
PR Newswire - Wed Feb 26, 3:00PM CST
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) today announced Dr. Sharon Mates, Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 34th Annual Healthcare Conference on March 3, 2014 at 2:50 p.m. Eastern Time in Boston, MA. Dr. Mates will provide a corporate overview and business update.
Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2013 Research Report
M2 - Fri Feb 14, 3:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/5m252n/cognitive) has announced the addition of the "Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2013" report to their offering. 'Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS). Scope - A snapshot of the global therapeutic scenario for Cognitive Impairment Associated With Schizophrenia (CIAS). - A review of the Cognitive Impairment Associated With Schizophrenia (CIAS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Cognitive Impairment Associated With Schizophrenia (CIAS) Overview Therapeutics Development Clinical Stage Products Early Stage Products Unknown Stage Products Drug Profiles AQW-051 - Drug Profile AVN-211 - Drug Profile eltoprazine - Drug Profile ABT-126 - Drug Profile erteberel - Drug Profile ITI-214 - Drug Profile SKL-15508 - Drug Profile AN-761 - Drug Profile Alpha-7 Program - Drug Profile SEN-15924 - Drug Profile PNU-120596 - Drug Profile A-582941 - Drug Profile A-431404 - Drug Profile MGluR5 PAM - Drug Profile CDD-0304 - Drug Profile NR-2B Positive Allosteric Modulators - Drug Profile Product Description Mechanism of Action R&D Progress Featured News & Press Releases Appendix Companies Mentioned Eli Lilly and Company Avineuro Pharmaceuticals, Inc. Novartis AG Pfizer Inc. Mithridion, Inc. Upsher-Smith Laboratories, Inc. PsychoGenics, Inc. Siena Biotech S.p.A. Intra-Cellular Therapies, Inc. Mnemosyne Pharmaceuticals, Inc. SK Biopharmaceuticals Co., Ltd. Merz Pharmaceuticals GmbH AbbVie Inc. Aniona ApS For more information visit http://www.researchandmarkets.com/research/5m252n/cognitive About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Intra-Cellular Therapies to Present at Two Upcoming Healthcare Conferences
PR Newswire - Fri Feb 07, 7:00AM CST
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) today announced Dr. Sharon Mates, Ph.D., President and Chief Executive Officer, will present at the 16th Annual BIO CEO and Investor Conference on February 10, 2014 at 4:30 p.m. Eastern Time at the Waldorf Astoria New York. Dr. Mates is also scheduled to present in a fireside chat discussion at the 2014 Leerink Global Healthcare Conference on February 12th, 2014 at 08:50 a.m. Eastern Time also at the Waldorf Astoria New York.
Intra-Cellular Therapies Announces Completion of Public Offering and Exercise of Option to Purchase Additional Shares
PR Newswire - Wed Feb 05, 12:04PM CST
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company focused on the development of therapeutics for CNS disorders, today announced the completion of its previously announced underwritten public offering of 6,142,000 shares of its common stock at a public offering price of $17.50 per share. In addition, the underwriters have exercised in full their option to purchase an additional 921,300 shares of common stock at the public offering price.
Intra-Cellular Therapies Announces Pricing of Public Offering of Common Stock; To Begin Trading on NASDAQ Global Select Market under "ITCI"
PR Newswire - Thu Jan 30, 8:15PM CST
Intra-Cellular Therapies, Inc. (OTCQB: ITCI), a biopharmaceutical company focused on the development of therapeutics for CNS disorders, today announced the pricing of an underwritten public offering of 6,142,000 shares of its common stock at a public offering price of $17.50 per share. In addition, Intra-Cellular has granted the underwriters a 30-day option to purchase up to an additional 921,300 shares of common stock. In connection with the offering, shares of Intra-Cellular common stock will commence trading on the NASDAQ Global Select Market tomorrow morning under the ticker "ITCI."
Intra-Cellular Therapies Cleared for Quotation on OTCQB
PR Newswire - Thu Dec 19, 6:25PM CST
Intra-Cellular Therapies, Inc. ("ITI"